Perbedaan MNC Energy Investments Tbk. dan Organon Pharma Indonesia Tbk.: MNC Energy Investments Tbk. diperdagangkan di Rp126 (kapitalisasi pasar 4 T, volume 24 jam 597,37 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: MNC Energy Investments Tbk. jauh lebih besar — sekitar 38,3× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| IATA | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 4 T | 104,4 M |
Volume | 597,37 jt | — |
Lot | 5,97 jt | — |
Perputaran | 75,35 M | — |
Harga Rata-rata | 126,13 | — |
Nilai Transaksi | 75,35 M | — |
Harga Ekuilibrium Indikatif | 126 | — |
Volume Ekuilibrium Indikatif | 168,2 rb | — |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT MNC Energy Investments Tbk (“Company”) was established based on Deed No. 14 dated September 10, 1968 of Notary Frederik Alexander Tumbuan. The Deed of Establishment was approved by the Ministry of Justice of the Republic of Indonesia, in its Letter No. JA5/18/21 dated April 15, 1969. The Company’s Articles of Association has been amended several times, most recently by Deed No. 102 dated December 15, 2022 of Notary Aulia Taufani SH, Notary in South Jakarta.The Company engaged in investments focusing on the energy sector, particularly coal mining. The Company take over 99,33% of PT Bhakti Coal Resources (“BCR”) shares from PT MNC Asia Holding Tbk. BCR is the parent company of eight coal companies with Mining Business Licenses (IUP) in Musi Banyuasin, South Sumatera. The total mining area is approximately 72.478 Ha with estimated total resources of up to 1.6 billion MT.The Company also has other subsidiaries that developed various types of business, such as mining service and port management through PT MNC Infrastruktur Utama, air charter services through PT Indonesia Air Transport, aircraft repair and maintenance through PT Global Maintenance Facility, and PT Bhakti Migas Resources.
Selengkapnya di halaman IATA →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →